Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab and BI 754111 in Asian patients with advanced solid tumors
NCT03433898Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2018
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ezabenlimab in Neoplasm (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Dose-Limiting Toxicity at 3 weeks and 1 more. Started Feb 2018; status: completed.
02
Drugs
ezabenlimab
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT03433898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433898.